Protocols

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

→ Astellas and FibroGen are reporting that their fourth late-stage study of roxadustat hit the primary endpoint for anemia in patients with CKD.

→ North Carolina’s vTv Therapeutics watched its stock $VTVT soar over 40% on the news that its entered a licensing deal with Newsoara Biopharma. The agreement allows Newsoara to develop and commercialize vTv’s PDE4 inhibitor program in China, Hong Kong, Macau, Taiwan, and other Pacific Rim countries.  Newsoara will develop the clinical stage drug, called HPP737, for respiratory and other inflammatory diseases, according to a company statement.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->